ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2155

Risk Factors and Outcomes of Post-Transplant Erythrocytosis Among Adult Kidney Transplant Recipients: A Systematic Review and Meta-Analysis

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Mekraksakit, Poemlarp, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Boonpheng, Boonphiphop, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Leelaviwat, Natnicha, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Duangkham, Samapon, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Deb, Anasua, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Nugent, Kenneth, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Cheungpasitporn, Wisit, Mayo Clinic Minnesota, Rochester, Minnesota, United States
Background

Post-transplant erythrocytosis (PTE) can occur in up to 10-16% after kidney transplant (KT). However, the post-transplant outcomes of recipients with PTE in the literature were conflicting. We performed systematic review and meta-analysis of published studies to evaluate risk factors of PTE as well as outcomes of recipients who developed PTE compared to controls.

Methods

A literature search was conducted evaluating all literature from existence through February 2, 2021, using MEDLINE and EMBASE. Data from each study were combined using the random-effects model. (PROSPERO: CRD42021230377)

Results

Thirty-nine studies from July 1982 to January 2021 were included (7,099 KT recipients). The following factors were associated with PTE development: male gender (pooled RR=1.62 [1.38, 1.91], I2=39%), deceased-donor KT (pooled RR=1.18 [1.03, 1.35], I2=32%), history of smoking (pooled RR=1.36 [1.11, 1.67], I2=13%), underlying polycystic kidney disease (PKD) (pooled RR=1.56 [1.21, 2.01], I2=44%), and pretransplant dialysis (pooled RR=1.6 [1.02, 2.51], I2=46%). However, PTE was not associated with outcomes of interest including overall mortality, death-censored graft failure, and thromboembolism.

Conclusion

Our meta-analysis demonstrates that male gender, deceased donor, history of smoking, underlying PKD, and pretransplant dialysis were significantly associated with developing PTE. However, with proper management, PTE has no impact on the prognosis of KT patients.

Forest plots of the included studies assessing the association between PTE in KT patients and outcomes of (A) Overall mortality, (B) DCGF, (C) Thromboembolism